Fibrinogen is a predictor of mortality in coronary heart disease patients

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 3, 1996, Pages 351-356

  Benderly, Michal ^a   Graff, Eran ^b   Reicher Reiss, Henrietta ^a   Behar, Solomon ^a   Brunner, Daniel ^b   Goldbourt, Uri ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

coronary disease; fibrinogen; mortality; prospective study; risk factors

Indexed keywords

FIBRINOGEN;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CORONARY RISK; FIBRINOGEN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

EID: 0029915607     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.3.351     Document Type: Article

References (22)

1. Meade TW, North WRS, Chakrabarti RR, Stirling Y, Haines AP, Thompson SG. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980;1:1050-1054.
2. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
3. Stone MC, Thorp J. Plasma fibrinogen: a major coronary risk factor. J R Coll Gen Pract. 1985;35:564-569.
4. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA. 1987;258:1183-1186.
5. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation. 1991;83:836-844.
6. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb. 1994;14:54-59.
7. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta analysis and review of the literature. Ann Intern Med. 1993;118:956-963.
8. Meade TW, Mellows W, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart study. Lancet. 1986;2:533-537.
9. Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, Meade TW. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost. 1992;68:261-263.
10. Martin JF, Bath PMW, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991;338:1409-1411.
11. Goldbourt U, Behar S, Reicher-Reiss H, et al for the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum HDL cholesterol and reducing triglycerides after myocardial infarction in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention study). Am J Cardiol. 1993;71:909-915.
12. Hemker HC, Kop J, Willems GM. Kinetic aspects of the interaction of blood clotting enzymes, VII: the relation between clotting time and clotting velocity. Thromb Haemost. 1979;41:309-313.
13. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
14. SAS/STAT User's Guide, Version 6. 4th ed. Cary, NC: SAS Institute Inc; 1987;1:943 and 1987;2:620.
15. SAS/STAT User's Guide, Version 6. 4th ed. Cary, NC: SAS Institute Inc; 1987;1:943 and 1987;2:620.
16. SAS/STAT software: changes and enhancements, release 6.07. Cary, NC: SAS Institute Inc; 1992:620. SAS technical report P-229.
17. Yaari S, Goldbourt U. A SAS program for evaluating person-years of risk in cohort studies. Comp Biol Med. 1989;19:353-359.
18. Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J. 1993;69:338-342.
19. Barasch E, Benderly M, Graff E, Behar S, Reicher-Reiss H, Caspi A, Peled B, Reisin L, Roguin N, Goldbourt U. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients: the Bezafibrate Infarction Prevention (BIP) study. J Clin Epidemiol. 1996;48:757-765.
20. Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Study. J Clin Epidemiol. 1990;16:83-88.
21. Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet. 1993;342:84-86.
22. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 1994;90:2236-2240.